Sorenson John Bradley

SEC source: 0001225208-22-002934 · doc4.xml · derivative · entry 5

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 1,500 shares

Expires 2025-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

SEC source: 0001225208-22-002934 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,620

SEC source: 0001225208-22-002934 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,079

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-22-002701 · doc4.xml · derivative · entry 6

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,558

Underlying: Common Stock · 14,558 shares

Expires 2032-02-16

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

SEC source: 0001225208-22-002701 · doc4.xml · derivative · entry 5

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,091

Underlying: Common Stock · 5,091 shares

Expires 2026-02-16

F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

SEC source: 0001225208-22-002701 · doc4.xml · derivative · entry 4

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,200

Underlying: Common Stock · 1,200 shares

Expires 2023-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

SEC source: 0001225208-22-002701 · doc4.xml · nonDerivative · entry 3

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,579

SEC source: 0001225208-22-002701 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,947

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-22-002701 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,747

SEC source: 0001225208-22-001614 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,514

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.20 to $43.205, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-22-000117 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,929 shares

Expires 2021-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

F1 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

F1 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

SEC source: 0001225208-22-000117 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,681

SEC source: 0001225208-22-000117 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

SEC source: 0001225208-21-007384 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,134

SEC source: 0001225208-21-007384 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,920

SEC source: 0001225208-21-004229 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,222

Underlying: Common Stock · 1,222 shares

Expires 2022-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-21-004229 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,492

SEC source: 0001225208-21-004229 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,866

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-21-003529 · doc4.xml · derivative · entry 7

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,202

Underlying: Common Stock · 4,202 shares

Expires 2022-12-31

F4 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F5 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022.

F5 · derivative.exercise_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022.

F5 · derivative.expiration_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022.

F5 · balance_after: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022.

SEC source: 0001225208-21-003529 · doc4.xml · derivative · entry 6

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,594 shares

Expires 2021-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-21-003529 · doc4.xml · nonDerivative · entry 4

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,644

SEC source: 0001225208-21-003529 · doc4.xml · nonDerivative · entry 3

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,132

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-21-003529 · doc4.xml · derivative · entry 5

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,181

Underlying: Common Stock · 1,090 shares

Expires 2023-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.

SEC source: 0001225208-21-003529 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,538

SEC source: 0001225208-21-003529 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,872

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-21-003184 · doc4.xml · derivative · entry 5

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,558

Underlying: Common Stock · 1,185 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.

F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.

SEC source: 0001225208-21-003184 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,782

SEC source: 0001225208-21-003184 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,145

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-21-003184 · doc4.xml · derivative · entry 4

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,296

Underlying: Common Stock · 19,296 shares

Expires 2031-02-17

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

SEC source: 0001225208-21-003184 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2025-02-17

F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

SEC source: 0001225208-21-002712 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,400

Underlying: Common Stock · 1,200 shares

Expires 2023-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

SEC source: 0001225208-21-002712 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,960

SEC source: 0001225208-21-002712 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,328

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-21-002246 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,128

SEC source: 0001225208-21-002246 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,560

F1 · shares: On February 15, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2020 and subject to the completion of the concurrent three-year individual service period. On February 9, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-21-000244 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,071 shares

Expires 2020-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020.

F1 · derivative.exercise_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020.

F1 · derivative.expiration_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020.

SEC source: 0001225208-21-000244 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,882

SEC source: 0001225208-21-000244 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,242

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020.

SEC source: 0001225208-20-011061 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,171

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.06 to $39.0701, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-20-004166 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,444

Underlying: Common Stock · 1,222 shares

Expires 2022-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-20-004166 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,671

SEC source: 0001225208-20-004166 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-20-003572 · doc4.xml · derivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,929

Underlying: Common Stock · 3,929 shares

Expires 2021-12-31

F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021.

F2 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021.

F2 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021.

F2 · balance_after: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021.

SEC source: 0001225208-20-003300 · doc4.xml · derivative · entry 9

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,533 shares

Expires 2020-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

SEC source: 0001225208-20-003300 · doc4.xml · nonDerivative · entry 6

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,823

SEC source: 0001225208-20-003300 · doc4.xml · nonDerivative · entry 5

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,293

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-20-003300 · doc4.xml · derivative · entry 8

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,594

Underlying: Common Stock · 1,593 shares

Expires 2021-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-20-003300 · doc4.xml · nonDerivative · entry 4

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,760

SEC source: 0001225208-20-003300 · doc4.xml · nonDerivative · entry 3

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,248

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-20-003300 · doc4.xml · derivative · entry 7

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,271

Underlying: Common Stock · 1,090 shares

Expires 2023-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.